Prevention of cardiovascular events in variant angina by long-term diltiazem therapy.
In 43 patients with variant angina, the cardiovascular event rate during diltiazem therapy was compared with that in an equal time period before initiation of therapy. Cardiovascular events, that is, myocardial infarction, sudden death and hospitalization for prolonged angina, were decreased significantly (p less than 0.01) during the initial 6 months and mean 19.6 months of therapy. Based on the binomial principle, there were 22 events during the mean 19.6 months before therapy and 2 events during the equal time period on therapy. No patient died during follow-up. The frequency of angina was decreased by 94%. Diltiazem was well tolerated by all patients and no patient had to discontinue therapy because of adverse effects. It is concluded that long-term diltiazem therapy reduces cardiovascular events in patients with variant angina.
D000328:Adult; D000368:Aged; D000788:Angina Pectoris, Variant / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D003329:Coronary Vasospasm / Q000188:drug therapy*; D003645:Death, Sudden; D004110:Diltiazem / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D013997:Time Factors
D001552:Benzazepines; D004110:Diltiazem